Severe asthma: comorbidities and new frontiers in therapy and management

Abstract

Asthma is a heterogeneous inflammatory disease that affects around 5-10% of children globally. Up to 2% of pediatric asthmatic patients suffer from severe asthma, which leads to increased hospitalizations, higher healthcare costs, and poorer outcomes despite intensive standard treatment. Within this context, the endotype-driven approach and use of biologics have provided significant benefits in treating severe asthma and its associated comorbidities. Additionally, the emerging role of digital health may greatly reduce the global burden of asthma